onr:"swepub:oai:lup.lub.lu.se:0f82dea2-e565-489c-a553-8bfe6280b66a"
Sökning: onr:"swepub:oai:lup.lub.lu.se:0f82dea2-e565-489c-a553-8bfe6280b66a" > Testing the SF-36 i...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
- Hagell, PeterLund University,Lunds universitet,Institutionen för hälsovetenskaper,Medicinska fakulteten,Äldres hälsa och personcentrerad vård,Forskargrupper vid Lunds universitet,Department of Health Sciences,Faculty of Medicine,Older people's health and Person-Centred care,Lund University Research Groups (författare)
Testing the SF-36 in Parkinson's disease : Implications for reporting rating scale data.
- Artikel/kapitelEngelska2008
Förlag, utgivningsår, omfång ...
- 2008-01-22
- Springer Science and Business Media LLC,2008
Nummerbeteckningar
- LIBRIS-ID:oai:lup.lub.lu.se:0f82dea2-e565-489c-a553-8bfe6280b66a
- https://lup.lub.lu.se/record/1021307URI
- https://doi.org/10.1007/s00415-008-0708-yDOI
Kompletterande språkuppgifter
- Språk:engelska
- Sammanfattning på:engelska
Ingår i deldatabas
- SwePubSwePub
Klassifikation
Anmärkningar
- Rating scales are increasingly the primary outcome measures in clinical trials. However, clinically meaningful interpretation of such outcomes requires that the scales used satisfy basic requirements (scaling assumptions) within the data. These are rarely tested. The SF-36 is the most widely used patient-reported rating scale. Its scaling assumptions have been challenged in neurological disorders but remain untested in Parkinson's disease (PD).We therefore tested these by analyzing SF-36 data from 202 PD patients (54% men; mean age 70) to determine if it was legitimate to report scores for the eight SF-36 scales and its two summary measures of physical and mental health, and if those scores were reliable and valid. Results supported generation of the eight SF-36 scale scores and their reliabilities were generally good (>/= 0.74 in all but one instance). However, we found limitations that question the meaningfulness of four scales and other limitations that restrict the ability of four scales to detect change in clinical trials (floor/ceiling effects, 19.6-46.2 %). The two SF-36 summary measures were not found to be valid indicators of physical and mental health. This study demonstrates important limitations of the SF-36 and provides the first evidence- based guidelines for its use in PD. The limitations of the SF-36 demonstrated here may explain some unexpected findings in previous studies. However, the main implication is a general one for the clinical research community regarding requirements for reporting rating scale endpoints. Specifically, investigators should routinely provide scale evaluations based on data from within major clinical trials.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
- Törnqvist, Anna LenaLund University,Lunds universitet,Neurokirurgi,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Neurosurgery,Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)neur-ato (författare)
- Hobart, J (författare)
- Institutionen för hälsovetenskaperMedicinska fakulteten (creator_code:org_t)
Sammanhörande titlar
- Ingår i:Journal of Neurology: Springer Science and Business Media LLC255:2, s. 246-2541432-14590340-5354
Internetlänk
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Hagell, Peter
- Törnqvist, Anna ...
- Hobart, J
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Neurologi
- Artiklar i publikationen
- Journal of Neuro ...
- Av lärosätet
- Lunds universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
